Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Public ClinicalTrials.gov record NCT02269592. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome
Study identification
- NCT ID
- NCT02269592
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Enrollment
- 10,000 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2014
- Primary completion
- Nov 30, 2027
- Completion
- Aug 31, 2030
- Last update posted
- May 6, 2026
2014 – 2030
United States locations
- U.S. sites
- 7
- U.S. states
- 3
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | Recruiting |
| Dana Farber Cancer Institute at St. Elizabeth's | Brighton | Massachusetts | 02135 | Recruiting |
| Dana Farber Cancer Institute at Merrimack Valley | Methuen | Massachusetts | 01844 | Recruiting |
| Dana Farber Cancer Institute at Milford Regional Medical Center | Milford | Massachusetts | 01757 | Recruiting |
| Dana Farber Cancer Institute at South Shore | Weymouth | Massachusetts | 02190 | Recruiting |
| West Michigan Cancer Center | Kalamazoo | Michigan | 49007 | Recruiting |
| Dana Farber/New Hampshire Oncology-Hematology | Londonderry | New Hampshire | 03053 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02269592, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2026 · Synced May 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02269592 live on ClinicalTrials.gov.